Business Name: |
Pathopartitions |
Contact Person: |
Franz Fogt |
Address: |
3160 Chestnut St # 200, Philadelphia, Pennsylvania 19104 |
Phone Number: |
(610) 642-8768 |
Annual Revenue (USD): |
$50.000 to $99.999 |
Founding Year: |
2012 |
Location Type: |
Single Location |
Employee Number: |
1 to 4 |
Business Type: |
B2B (Business to Business) |
Business Category: |
Commercial Biotechnical Research |
SIC Code: |
8731 |
NAICS Code: |
541711 |
Share This Business: |
|
Related Businesses: |
Oncovirx - Philadelphia, PA 19104 Intervir Therapeutics - Philadelphia, PA 19104 Diathera LLC - Philadelphia, PA 19104 Vibe Pharmaceuticals - Philadelphia, PA 19104 Biotech Studio LLC - Philadelphia, PA 19104 Aum Lifetech Inc - Philadelphia, PA 19104 Metamorphosis LLC - Philadelphia, PA 19104 Microbiota Therapeutics - Philadelphia, PA 19104 Penzymes LLC - Philadelphia, PA 19104 Navirx LLC - Philadelphia, PA 19104 Betaplus Radiopharmaceuticals LLC - Philadelphia, PA 19104 Lignamed LLC - Philadelphia, PA 19104 Pathonomics - Philadelphia, PA 19104 Amyndas Biotherapeutics LLC - Philadelphia, PA 19104 Skelegen - Philadelphia, PA 19104 Cartcentric Diagnostics - Philadelphia, PA 19104 Liquid Biotech - Philadelphia, PA 19104 Epigen Cardio LLC - Philadelphia, PA 19104 Vector Biosystems - Philadelphia, PA 19104 |
The company Pathopartitions provides B2B services in the form of Commercial Biotechnical Research from its single location in Pennsylvania.
1 to 4 employees work for Pathopartitions, and the business now earns $50.000 to $99.999 per annum.
Pathopartitions was launched in 2012 and is classified under SIC code and category 8731 , and NAICS number and grouping 541711 .
To contact Pathopartitions, please call Franz Fogt with the phone number (610) 642-8768 or visit its single location at 3160 Chestnut St # 200 in Philadelphia, Pennsylvania 19104.
The location of the single location can also be found using the coordinates 39.953553,-75.18659.
Read more details about this business on the webpage or follow the company’s social media accounts, on Twitter and on Facebook.